Inactive Instrument

Bausch Health Companies Inc Stock price Toronto S.E.

Equities

CA91911K1021

Pharmaceuticals

Sales 2024 * 9.39B 12.77B Sales 2025 * 9.21B 12.52B Capitalization 3.83B 5.21B
Net income 2024 * 220M 299M Net income 2025 * 11M 14.96M EV / Sales 2024 * 2.53 x
Net Debt 2024 * 19.91B 27.07B Net Debt 2025 * 18.33B 24.93B EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
16.7 x
P/E ratio 2025 *
525 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Toronto healthcare stocks rise in flat market, Canada Goose slides RE
Billionaires sought to help fund Trump bond in civil fraud case, sources say RE
Trump floats billionaire Paulson as potential Treasury chief, Bloomberg reports RE
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma CI
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
TSX closes at 22-month high powered by tech rally RE
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
Toronto Stocks Climb, Loblaw Shares Rise on 4Q Profit, Revenue Growth DJ
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell MT
Transcript : Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024
More news
Managers TitleAgeSince
Chief Executive Officer 61 -
Director of Finance/CFO 51 22-05-23
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 08-07-31
Chairman 68 17-05-31
Director/Board Member 35 21-03-16
More insiders
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
More about the company
  1. Stock
  2. Equities
  3. Stock Bausch Health Companies Inc.
  4. Stock Bausch Health Companies Inc - Toronto S.E.